In Reply: Mr Anesi underscores a key point in our Commentary. It is entirely possible that genomic profiling or other developing technologies will guide better patient selection for systemic therapy for breast cancer. That is why we emphasize the appropriateness of using preoperative chemotherapy in the context of clinical trials and urge community support for these efforts.
Hudis CA, Modi S. Genetically Guided Choices for Chemotherapy—Reply. JAMA. 2008;299(13):1543-1544. doi:10.1001/jama.299.13.1544-b